The Chicago-based company posted profits of $90.4 million, or $1.33 per share, on sales of $759.2 million for the three months ended Sept. 30, amounting to a bottom-line gain of 30.3% on sales growth of 2.8% compared with Q3 2017. Adjusted to exclude one-time items, earnings per share were $1.63, a full 12¢ above the average on Wall Street, where analysts were looking for sales of $750.9 million.
Full-year profits were up a whopping 88.9% to $252.4 million, or $3.73 per share, on sales growth of 3.8% to $2.85 billion compared with fiscal 2017. Adjusted EPS were $4.75, 11¢ ahead of The Street, which had pegged annual sales at $2.84 billion.
“We are very pleased with the momentum generated by our core business and strong financial results in the fourth quarter,” president & CEO John Groetelaars said in prepared remarks. “Our performance reflects the diversity of our portfolio, strong new product contributions, and solid execution in driving sustainable revenue growth and double-digit growth in adjusted earnings per share, while delivering on our long-range financial objectives.”
Hill-Rom said it expects to log adjusted EPS of $5.08 to $5.16 for fiscal 2019, on sales growth of 1% to 2% reported and 2% to 3% on a constant-currency basis. First-quarter adjusted EPS are forecast to be between 97¢ and 99¢ on reported sales growth of 1% and 2 to 3% in constant-currency terms.
The news sent HRC shares up 6.0% to $92.00 apiece today in mid-morning trading.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.